Characterization, stability and in-vivo distribution of asialofetuin glycopeptide incorporating DSPC/CHOL liposomes prepared by mild cholate incubation
P. Kallinteri et al., Characterization, stability and in-vivo distribution of asialofetuin glycopeptide incorporating DSPC/CHOL liposomes prepared by mild cholate incubation, J DRUG TAR, 9(2), 2001, pp. 155-168
In this study, a small triantennary asialoglycopeptide of fetuin (A-F-2) wa
s used as a ligand to direct liposomes to hepatocytes. A-F2 was cleaved fro
m asialofetuin, purified, conjugated with fatty acids and incorporated into
pre-formed sonicated DSPC/Chol (2:1) liposomes. A mild cholate incubation
method for incorporating the A-F2 ligand on pre-formed vesicles was used. I
n preliminary in vivo experiments In-111(3+) encapsulated in A-F-2/palmityl
liposomes was seen to accumulate in the liver of mice significantly faster
than when encapsulated in non-ligand bearing liposomes of the same lipid c
omposition (studied before), justifying further investigation of this syste
m. The presence of the A-F-2/fatty acid conjugate in a functional form on t
he vesicle surface was confirmed by their reversible agglutination in the p
resence of Ricinus communis agglutinin (RCA(120)). Effects of ligand incorp
oration on the vesicle size distribution, z-potential, membrane integrity a
nd stability were monitored. The results demonstrate that highest ligand in
corporation was achieved when liposomes and ligand were co-incubated in the
presence of 1mM sodium cholate. Incorporation increased with the length of
the fatty acid used for A-F2 conjugation. Ligand-bearing liposomes were de
monstrated to be smaller in diameter (about 30%) with a more positive z-pot
ential in comparison to control vesicles while ligand incorporation did not
influence the liposome membrane integrity. The size of the ligand-incorpor
ating vesicles was maintained after 24 hours of incubation in isotonic buff
er, proving that the vesicles do not aggregate. Although the preliminary bi
odistribution results may suggest that ligand bearing liposomes are accumul
ating in the liver, further cell culture in vivo distribution and especiall
y liver fractionation studies are required in order to clarify the intrahep
atic localization of these liposomes and the ability to target liver hepato
cytes in vivo.